Therapeutic antibodies directed at G protein-coupled receptors

150Citations
Citations of this article
290Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

G protein-coupled receptors (GPCRs) are one of the most important classes of targets for small molecule drug discovery, but many current GPCRs of interest are proving intractable to small molecule discovery and may be better approached with bio-therapeutics. GPCRs are implicated in a wide variety of diseases where antibody therapeutics are currently used. These include inflammatory diseases such as rheumatoid arthritis and Crohn disease, as well as metabolic disease and cancer. Raising antibodies to GPCRs has been difficult due to problems in obtaining suitable antigen because GPCRs are often expressed at low levels in cells and are very unstable when purified. A number of new developments in overexpressing receptors, as well as formulating stable pure protein, are contributing to the growing interest in targeting GPCRs with antibodies. This review discusses the opportunities for targeting GPCRs with antibodies using these approaches and describes the therapeutic antibodies that are currently in clinical development. © 2010 Landes Bioscience.

Cite

CITATION STYLE

APA

Hutchings, C. J., Koglin, M., & Marshall, F. H. (2010, November). Therapeutic antibodies directed at G protein-coupled receptors. MAbs. https://doi.org/10.4161/mabs.2.6.13420

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free